Seiwerth, S., Milavic, M., Vukojevic, J., Gojkovic, S., Krezic, I., Vuletic, L
Gastrointestinal Disorders: Treats ulcers, acid reflux, Crohns disease, and leaky gut
compounded under Section 503A for individual prescriptions Hepatic impairment data / no controlled pharmacokinetic studies in liver disease populations Copper clearance / 85-95% of circulating copper is bound to ceruloplasmin, which is synthesized exclusively in the liver [1] Wilson disease parallel / hepatic copper accumulation can reach 250+ mcg/g dry weight in impaired biliary excretion [2] Child-Pugh A / may proceed with standard dosing and baseline copper labs Child-Pugh B / dose reduction recommended with monthly copper monitoring Child-Pugh C / use generally not recommended due to impaired biliary copper excretion Standard compounded dose / 1-2 mg subcutaneously daily or 3 times weekly Key monitoring labs / serum copper, ceruloplasmin, 24-hour urine copper, liver function tests What Is GHK-Cu and How Does It Work
In the context of 5-Amino-1MQ vs MOTS-c, which is considered an exercise mimetic